Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

News & Events

News & Events menu

Press Releases
Events

CSS to format presentations

January 2021 Corporate Presentation

lnk News

Press Releases

View All

January 21, 2021

Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

December 30, 2020

Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers

December 21, 2020

New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of Cancer

lnk Past Events

Events

View Past Events

December 2, 2020 at 4:45 PM EST

Evercore ISI 3rd Annual HealthCONx Conference

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2021 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter